Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.
Cancer and Genetics
A new multianalyte test simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood, offering clinicians and patients a potentially affordable way of detecting cancer at an earlier stage.
In this slide show we highlight some of the top news from the past year on genetic testing for cancer, including gene signatures for identifying different sub-types of breast cancer, the influence of genetics on RCC outcomes, and the utility of liquid biopsies.
Investigators found a methylation-independent loss of MYO5B expression in CRC that matched disease progression, which indicates that the use of MYO5B alone or in combination with its adapter protein RAB8A is a prognostic marker for the disease.
A recent study showed that molecular tumor boards coupled with cognitive computing with IBM's Watson could improve patient care by providing a rapid, comprehensive approach for data analysis.
A novel classification system that incorporates genomic risk with clinical variables was able to accurately identify prostate cancer patients at low, intermediate, and high risk for metastasis.
A precision medicine clinical trial based on genomic abnormalities has screened nearly 6,000 patients in just under 2 years and matched 18% of tumors screened with a genetic mutation to one of 30 treatment arms.
The FDA has approved the first gene therapy available in the United States, tisagenlecleucel (Kymriah), for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Here we review the clinical data supporting these different plasma genotyping methodologies, and present a practical approach to the interpretation of the results of these tests.
A 70-gene expression score can identify women with indolent breast cancer at “ultralow” risk, according to a new study. Women with such a score have extremely low risk of disease-specific mortality over 20 years without systemic therapy.